Skip to main content

Table 2 Baseline characteristics of patients in the post hoc subgroup analysis

From: A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

Parameter Better efficacy subgroup ITT population
FOLFIRI-Placebo FOLFIRI-Aflibercept FOLFIRI-Placebo FOLFIRI-Aflibercept
(n = 406) ( n = 404) ( n = 614) ( n = 612)
Gender, n (%)     
Female 174 (42.9) 153 (37.9) 261 (42.5) 247 (40.4)
Male 232 (57.1) 251 (62.1) 353 (57.5) 365 (59.6)
Mean age, y (range) 59.9 (25–86) 59.4 (21–82) 60.2 (19–86) 59.5 (21–82)
Age group, n (%)     
<65 y 254 (62.6) 277 (68.6) 376 (61.2) 407 (66.5)
≥65 but <75 y 133 (32.8) 108 (26.7) 199 (32.4) 172 (28.1)
≥75 y 19 (4.7) 19 (4.7) 39 (6.4) 33 (5.4)
Race, n (%)     
Asian 29 (7.1) 23 (5.7) 51 (8.3) 35 (5.7)
Black 14 (3.4) 11 (2.7) 27 (4.4) 16 (2.6)
White 355 (87.4) 361 (89.4) 523 (85.2) 548 (89.5)
Other 8 (2) 9 (2.2) 13 (2.1) 13 (2.1)
Cancer diagnosis category, n (%)  
Colon 187 (46.1) 188 (46.5) 302 (49.2) 289 (47.2)
Rectosigmoid 95 (23.4) 85 (21) 136 (22.1) 123 (20.1)
Rectum 123 (30.3) 129 (31.9) 174 (28.3) 197 (32.2)
Other 1 (0.2) 2 (0.5) 2 (0.3) 3 (0.5)
Number of organs with metastasis, n (%)     
  0 2 (0.5) 2 (0.5) 6 (1.0) 2 (0.3)
  1 237 (58.4) 230 (56.9) 271 (44.1) 256 (41.8)
  >1 167 (41.1) 172 (42.6) 337 (54.9) 354 (57.8)
Metastatic sites, n (%)     
  Liver 283 (69.7) 294 (72.8) 431 (70.2) 459 (75.0)
  Lung 160 (39.4) 152 (37.6) 277 (45.1) 271 (44.3)
  Lymph 88 (21.7) 100 (24.8) 181 (29.5) 173 (28.3)
Liver metastasis only, n (%) 134 (33) 141 (34.9) 146 (23.8) 153 (25.0)
ECOG performance status, n (%)     
  0 314 (77.3) 317 (78.5) 350 (57.0) 349 (57.0)
  1 92 (22.7) 87 (21.5) 250 (40.7) 250 (40.8)
  2 0 0 14 (2.3) 13 (2.1)
Prior bevacizumab, n (%)     
  Yes 133 (32.8) 132 (32.7) 187 (30.5) 186 (30.4)
  No 273 (67.2) 272 (67.3) 427 (69.5) 426 (69.6)
  1. ECOG, European Cooperative Oncology Group; FOLFIRI, 5-fluorouracil–leucovorin–irinotecan; ITT, intent to treat; PS, performance status.